ABSTRACT
In 24 subjects without upper gastrointestinal lesions, gastric pH was measured from 30 min before until 90 min after the administration of diclofenac sodium (50 mg), piroxicam (20 mg), or 500 mg acetylsalicylic acid. In all these cases a drop of gastric pH was recorded, which started with all the drugs 15 min after their administration and lasted throughout the recording. Pre-treatment with rosaprostol (2 g given 30 min before the start of the trial) prevented the drop in pH. Twenty subjects with chronic joint diseases were divided into two groups in a cross-over double-blind randomized experimental design. One group received piroxicam (20 mg) + rosaprostol (2 g) daily; the other group was treated with piroxicam 20 mg + placebo. The patients were clinically reviewed every week in a month and questioned about their symptoms. Statistical analysis demonstrated that patients with articular diseases treated with NSAIDs + rosaprostol exhibited a frequency and severity of symptoms lower than those recorded in subjects receiving NSAIDs + placebo. Rosaprostol was found to be capable of antagonizing the variations of gastric acid output induced by the oral administration of NSAIDs, and to prevent and treat the occurrence of digestive disorders when given in combination with NSAIDs. These effects result from the action of rosaprostol on the mucosal barrier, and this cytoprotective action is confirmed by the present study with continuous measurements of gastric pH.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Digestion/drug effects , Dyspepsia/prevention & control , Fatty Acids/pharmacology , Gastric Mucosa/drug effects , Prostanoic Acids/pharmacology , Adult , Aged , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Clinical Trials as Topic , Double-Blind Method , Drug Evaluation , Dyspepsia/chemically induced , Gastric Acidity Determination , Humans , Hydrogen-Ion Concentration , Middle Aged , Pain/chemically induced , Pain/prevention & control , Random AllocationABSTRACT
Daily administration of 900 mg dihydroxydibutylether (DHBE) produced a significant reduction of lithogenic index in patients with cholesterol gallstones. After treatment with placebo, in the same subjects the lithogenic index rises significantly. The activity of DHBE is not casual.
Subject(s)
Bile/drug effects , Butanols/pharmacology , Cholagogues and Choleretics/pharmacology , Cholelithiasis/drug therapy , Cholesterol/metabolism , Ethers/pharmacology , Adult , Bile/analysis , Female , Humans , Lipids/analysis , Male , Middle AgedABSTRACT
The AA., after the nosographic, etiopathogenetic and clinical description of the "gastroptosic disease", give their findings of a functional and morphologic (gastroscopic and histologic) study accomplished over 200 patients with stomac tonus and/or stomac position disturbances. This study, confirming the numerous anomalies of the gastric-secretory function, especially of the hyposecretory and/or hypohydrochloric type, demonstrates the high incidence of the macro- and microscopic changes on the gastric mucosa. The AA., on account of the gastric morpho-functional changes observed, discuss, finally, the possible pathogenetic mechanisms.
